In late October 2025, Point32Health, Massachusetts’ second-largest health insurer, announced its second major round of ...
New Scripps Research trial will explore the effects of Lilly’s GLP-1 drug on reducing the symptoms of the debilitating disease.
el agonista del GLP-1 de Eli Lilly comercializado como Mounjaro para el tratamiento de la diabetes y Zepbound para la pérdida de peso, afecta los síntomas durante un período de 12 meses. «Se ha ...
Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...
With a new generation of weight-loss drugs entering Indian markets, spelling hope for many, The Indian Express tracks the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback